COVID-19 monoclonal antibodies (mAb) are treatments available to people who have tested positive for COVID-19, exhibit mild to moderate symptoms of the disease, and who are at high risk of developing severe COVID-19. When given in the first few days of illness, treatments can prevent hospitalizations and/or severe complications caused by COVID-19.
Our research team is currently conducting telephone surveys of patients who may have tested positive for COVID-19, and experienced symptoms where you would complete telephone surveys at 2 weeks, 4 weeks, and 3 months from the date you diagnosed with COVID-19.
Go to the Participate in mAb Research page, click on "Request to take the survey" under the community members section.
Treating COVID-19 early with monoclonal antibodies, reduces your risk of hospitalization and death by up to 85%. Check out this NBC News story, featuring Dr. Anthony Fauci and UCHealth's Dr. Adit Ginde & Dr. Marion Sills. Watch now.
Read this Denver Post story about monoclonal antibody treatment from mAb Colorado's own Dr. Adit Ginde from UCHealth & Dr. Lindsey Fish from Denver Health. Read now.
The Colorado Department of Public Health & Environment (CDPHE) has issued an urgent advisory regarding the increasing spread of the COVID-19 Delta variant in Colorado.
According to CDPHE, since the first case of the variant in Colorado was identified in early May, it has spread to more than 24 counties throughout the state.
Public health experts say that the Delta variant poses a great risk of future large outbreaks unless we take action now. All health care providers are asked to:
Key updates as of June 18, 2021:
This project is funded by a grant from the National Institutes of Health (NIH) and National Center for Advancing Translational Sciences (NCATS) (award number UL1-TR002535-03S3).